JPS6351157B2 - - Google Patents
Info
- Publication number
- JPS6351157B2 JPS6351157B2 JP55129121A JP12912180A JPS6351157B2 JP S6351157 B2 JPS6351157 B2 JP S6351157B2 JP 55129121 A JP55129121 A JP 55129121A JP 12912180 A JP12912180 A JP 12912180A JP S6351157 B2 JPS6351157 B2 JP S6351157B2
- Authority
- JP
- Japan
- Prior art keywords
- add
- hydroxyl group
- phenyl
- chloroform
- formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 239000000843 powder Substances 0.000 claims description 11
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 10
- -1 halohydrin steroid Chemical class 0.000 claims description 7
- 238000004519 manufacturing process Methods 0.000 claims description 7
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 6
- 239000004593 Epoxy Substances 0.000 claims description 5
- 229910052751 metal Inorganic materials 0.000 claims description 5
- 239000002184 metal Substances 0.000 claims description 5
- 125000006239 protecting group Chemical group 0.000 claims description 4
- 150000003431 steroids Chemical class 0.000 claims description 4
- 125000005843 halogen group Chemical group 0.000 claims description 2
- 239000012442 inert solvent Substances 0.000 claims description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 32
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical group CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 25
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 12
- 229960000583 acetic acid Drugs 0.000 description 12
- 239000012362 glacial acetic acid Substances 0.000 description 11
- 239000002904 solvent Substances 0.000 description 11
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 10
- 150000001875 compounds Chemical class 0.000 description 8
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 7
- 238000000034 method Methods 0.000 description 7
- 238000003756 stirring Methods 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- ISULLEUFOQSBGY-UHFFFAOYSA-N 4-phenyl-1,2,4-triazole-3,5-dione Chemical compound O=C1N=NC(=O)N1C1=CC=CC=C1 ISULLEUFOQSBGY-UHFFFAOYSA-N 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 5
- 229910052739 hydrogen Inorganic materials 0.000 description 5
- 239000001257 hydrogen Substances 0.000 description 5
- 238000002329 infrared spectrum Methods 0.000 description 5
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 5
- 235000019341 magnesium sulphate Nutrition 0.000 description 5
- 238000002844 melting Methods 0.000 description 5
- 230000008018 melting Effects 0.000 description 5
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 5
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 4
- OFHCOWSQAMBJIW-AVJTYSNKSA-N alfacalcidol Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C OFHCOWSQAMBJIW-AVJTYSNKSA-N 0.000 description 4
- 238000010992 reflux Methods 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 238000005406 washing Methods 0.000 description 4
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 229910000042 hydrogen bromide Inorganic materials 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 239000011541 reaction mixture Substances 0.000 description 3
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 239000006227 byproduct Substances 0.000 description 2
- 239000007810 chemical reaction solvent Substances 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 238000000354 decomposition reaction Methods 0.000 description 2
- 238000009776 industrial production Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 238000001953 recrystallisation Methods 0.000 description 2
- 238000010898 silica gel chromatography Methods 0.000 description 2
- BJYLYJCXYAMOFT-RRXOBRNQSA-N (1r,3s,5z)-5-[(2e)-2-[(1r,3as,7ar)-1-[(2r)-5-hydroxy-6-methylheptan-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1h-inden-4-ylidene]ethylidene]-4-methylidenecyclohexane-1,3-diol Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCC(O)C(C)C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C BJYLYJCXYAMOFT-RRXOBRNQSA-N 0.000 description 1
- RSUDQJUKBUVQHK-DDPQNLDTSA-N (3r,9s,10r,13r,14r,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-4,9,11,12,14,15,16,17-octahydro-3h-cyclopenta[a]phenanthren-3-ol Chemical compound C1[C@@H](O)C=C[C@]2(C)[C@@H](CC[C@@]3([C@@H]([C@H](C)CCCC(C)C)CC[C@H]33)C)C3=CC=C21 RSUDQJUKBUVQHK-DDPQNLDTSA-N 0.000 description 1
- WRFWAYDBNCOWRA-UHFFFAOYSA-N 3,4-dichloro-1-(6-iodo-4-oxo-2-thiophen-2-ylquinazolin-3-yl)pyrrole-2,5-dione Chemical compound O=C1C(Cl)=C(Cl)C(=O)N1N1C(=O)C2=CC(I)=CC=C2N=C1C1=CC=CS1 WRFWAYDBNCOWRA-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- UCTLRSWJYQTBFZ-UHFFFAOYSA-N Dehydrocholesterol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)CCCC(C)C)CCC33)C)C3=CC=C21 UCTLRSWJYQTBFZ-UHFFFAOYSA-N 0.000 description 1
- KRHYYFGTRYWZRS-UHFFFAOYSA-N Fluorane Chemical compound F KRHYYFGTRYWZRS-UHFFFAOYSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000011612 calcitriol Substances 0.000 description 1
- GMRQFYUYWCNGIN-NKMMMXOESA-N calcitriol Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](CCCC(C)(C)O)C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C GMRQFYUYWCNGIN-NKMMMXOESA-N 0.000 description 1
- UCTLRSWJYQTBFZ-DDPQNLDTSA-N cholesta-5,7-dien-3beta-ol Chemical compound C1[C@@H](O)CC[C@]2(C)[C@@H](CC[C@@]3([C@@H]([C@H](C)CCCC(C)C)CC[C@H]33)C)C3=CC=C21 UCTLRSWJYQTBFZ-DDPQNLDTSA-N 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 238000010908 decantation Methods 0.000 description 1
- 238000005695 dehalogenation reaction Methods 0.000 description 1
- HWJHWSBFPPPIPD-UHFFFAOYSA-N ethoxyethane;propan-2-one Chemical compound CC(C)=O.CCOCC HWJHWSBFPPPIPD-UHFFFAOYSA-N 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 1
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 1
- 229910000040 hydrogen fluoride Inorganic materials 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 125000001325 propanoyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000003586 protic polar solvent Substances 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 238000007142 ring opening reaction Methods 0.000 description 1
- 238000007086 side reaction Methods 0.000 description 1
- YYEADNLMHYZIQS-UHFFFAOYSA-M sodium;acetate;hydroiodide Chemical compound [Na+].[I-].CC(O)=O YYEADNLMHYZIQS-UHFFFAOYSA-M 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000011647 vitamin D3 Substances 0.000 description 1
- QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 description 1
- 235000005282 vitamin D3 Nutrition 0.000 description 1
- 229940021056 vitamin d3 Drugs 0.000 description 1
Classifications
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Steroid Compounds (AREA)
Description
【発明の詳細な説明】
本発明は、1α位に水酸基を有する種々ビタミ
ンD3類、例えば1α―ヒドロキシビタミンD3，
1α，24―ジヒドロキシビタミンD3，1α，25―ジ
ヒドロキシビタミンD3，1α，24，25―トリヒド
ロキシビタミンD3等の合成中間体の製法に関す
る。DETAILED DESCRIPTION OF THE INVENTION The present invention provides various types of vitamin D3 having a hydroxyl group at the 1α position, such as 1α-hydroxyvitamin D3 ,
This invention relates to a method for producing synthetic intermediates such as 1α,24-dihydroxyvitamin D 3 , 1α,25-dihydroxyvitamin D 3 , and 1α,24,25-trihydroxyvitamin D 3 .
更に詳しくは、本発明は一般式で示される１
―エンステロイド誘導体の製法に関する。 More specifically, the present invention is directed to the general formula 1
- Concerning the production method of entosteroid derivatives.
（式中Ｒは有機残基を意味し、R1，R2は同一
又は異なつて各々水素原子、水酸基および保護さ
れた水酸基を意味し、R3は水素原子又は水酸基
の保護基を意味する。）
従来、1α―ヒドロキシビタミンD3類の製法と
して、金子等の方法（特開昭50−84555号公報、
同51−100056号公報）が知られている。この方法
には前記一般式で示される１―エンステロイド
類を酸化反応に付し対応する1α，2α―エポキシ
ド体を得る工程が含まれている。しかしながら、
この酸化反応においては1α―ヒドロキシル基の
導入が可能な1α，2α―エポキシド体の収率が約
30％と低く、本来不必要な1β，2β―エポキシド
体（一般式）が約60％副生しており工業生産上
不利な工程である。 (In the formula, R means an organic residue, R 1 and R 2 are the same or different and each means a hydrogen atom, a hydroxyl group, or a protected hydroxyl group, and R 3 means a hydrogen atom or a protecting group for the hydroxyl group. ) Conventionally, as a method for producing 1α-hydroxyvitamin D type 3 , the method of Kaneko et al.
51-100056) is known. This method includes the step of subjecting the 1-ene steroid represented by the above general formula to an oxidation reaction to obtain the corresponding 1α,2α-epoxide. however,
In this oxidation reaction, the yield of 1α,2α-epoxide, into which a 1α-hydroxyl group can be introduced, is approximately
This is a disadvantageous process for industrial production, as it produces about 60% of the 1β,2β-epoxide (general formula) as a by-product, which is as low as 30%.
（式中、Ｒ，R1，R2，R3は前記と同じものを
意味する。）
この点を解決すべく、本発明者等が鋭意研究し
た結果、1α―ヒドロキシビタミンD3類の合成に
は使用し得ない一般式で示される1β，2β―エ
ポキシド体を容易な手段により、もとの一般式
で示される１―エンステロイド類に変換する方法
を見い出し本発明を完成した。すなわち本発明は
一般式で示される1β，2β―エポキシコレスタ
―3β―オールステロイド誘導体を不活性溶媒中
ハロゲン化水素酸と反応させ一般式
（式中、Ｒ，R1，R2，R3は前記と同じものを
意味し、Ｘはハロゲン原子を意味する。）
で示されるハロヒドリンステロイド誘導体を製造
し、次いで不活性溶媒中金属粉を反応させること
を特徴とする一般式で示される１―エンステロ
イド誘導体の製造方法に関する。 (In the formula, R, R 1 , R 2 and R 3 have the same meanings as above.) In order to solve this problem, the present inventors conducted intensive research and found that the synthesis of 1α-hydroxyvitamin D 3 The present invention has been completed by discovering a method for converting the 1β,2β-epoxide compound represented by the general formula, which cannot be used in the following, into the 1-ene steroid represented by the original general formula by a simple means. That is, the present invention involves reacting a 1β,2β-epoxy cholester-3β-allsteroid derivative represented by the general formula with hydrohalic acid in an inert solvent to obtain the general formula (In the formula, R, R 1 , R 2 , R 3 have the same meanings as above, and X means a halogen atom.) The halohydrin steroid derivative represented by The present invention relates to a method for producing a 1-ene steroid derivative represented by the general formula, which is characterized by reacting powder.
本発明により従来不必要とされていた副生成物
が、再び製造工程で使用することが可能となり、
1α―ヒドロキシビタミンD3類の工業生産を有利
に又効果的に行うことが可能となつた。 With the present invention, by-products that were previously considered unnecessary can be used again in the manufacturing process,
It has become possible to advantageously and effectively carry out industrial production of 1α-hydroxyvitamin D type 3 .
本発明の方法における一般式，およびで
示される化合物において、Ｒは有機残基であり、
具体的には例えばメチル，エチル基等の低級アル
キル基、置換又は非置換のフエニル基等のアリー
ル基である。R1，R2は同一又は異なつて、各々
水素原子、水酸基又は保護された水酸基を意味
し、R3は水素原子又は水酸基の保護基を意味す
る。この際、保護基としては使用するハロゲン化
水素酸に安定な基であればよく、アセチル基、ベ
ンゾイル基、プロパノイル基等のアシル基が好ま
しい例として挙げられる。 In the compound represented by the general formula and in the method of the present invention, R is an organic residue,
Specifically, they include lower alkyl groups such as methyl and ethyl groups, and substituted or unsubstituted aryl groups such as phenyl groups. R 1 and R 2 are the same or different and each means a hydrogen atom, a hydroxyl group or a protected hydroxyl group, and R 3 means a hydrogen atom or a protecting group for the hydroxyl group. In this case, the protecting group may be any group as long as it is stable to the hydrohalic acid used, and preferred examples include acyl groups such as acetyl group, benzoyl group, and propanoyl group.
本発明の方法で化合物からを製造する段階
で1β，2β―エポキシド基を開環し1α―ハロゲン
―2β―ヒドロキシ基に導く工程に使用するハロ
ゲン化水素としては、塩化水素、臭化水素、ヨウ
化水素およびフツ化水素であり、これらは単独あ
るいは例えばヨウ化ナトリウム―酢酸というハロ
ゲン化水素類を発生する形で反応系に加えること
もできる。又、反応溶媒として水を溶解する系で
あればハロゲン化水素類を水溶液の形で用いるこ
ともできる。なお入手し易く反応性がすぐれてい
る点および危険性が少ない点から臭化水素酸水溶
液が好ましく用いられる。反応溶媒としてはハロ
ゲン化水素類に安定でしかもハロゲン化水素類お
よび化合物を溶解し、安定性を保持するもので
あれば使用可能である。このような溶媒の好まし
い例としては氷酢酸がある。氷酢酸は単独あるい
はクロロホルム、ジクロルメタン、酢酸エチル等
との混合物としても用いることができる。反応温
度、反応時間は適宜選択されるが、本反応は比較
的短時間に終了する。副反応を避け収率よく行わ
しめるには短時間で処理することが必要である。
好ましくは室温下で約10分、氷冷下では数10分で
行われる。 Hydrogen halides used in the process of ring-opening a 1β,2β-epoxide group to form a 1α-halogen-2β-hydroxy group in the step of manufacturing a compound according to the method of the present invention include hydrogen chloride, hydrogen bromide, and iodine. These are hydrogen hydride and hydrogen fluoride, and these can be added to the reaction system alone or in a form that generates hydrogen halides, such as sodium iodide-acetic acid. Further, hydrogen halides can be used in the form of an aqueous solution as long as the system dissolves water as the reaction solvent. Note that an aqueous solution of hydrobromic acid is preferably used because it is easily available, has excellent reactivity, and is less dangerous. As the reaction solvent, any solvent that is stable to hydrogen halides, dissolves the hydrogen halides and the compound, and maintains stability can be used. A preferred example of such a solvent is glacial acetic acid. Glacial acetic acid can be used alone or in a mixture with chloroform, dichloromethane, ethyl acetate, etc. Although the reaction temperature and reaction time are appropriately selected, this reaction is completed in a relatively short time. In order to avoid side reactions and achieve good yield, it is necessary to perform the treatment in a short time.
Preferably, it is carried out for about 10 minutes at room temperature, and for several tens of minutes under ice cooling.
反応混合物から化合物の単離・精製は常法に
より容易に行われるが、特に精製することなく次
の工程に付すことも可能である。 Isolation and purification of the compound from the reaction mixture can be easily carried out by conventional methods, but it is also possible to subject it to the next step without any particular purification.
化合物を金属粉で処理し化合物を得る工程
で、金属粉としてはアエン末、銅粉、スズ末等脱
ハロゲン化能を有するものであればよく、これら
の単独あるいは混合物として使用し得る。なお、
これらの金属は表面のみで反応が起るため微粉末
であることが好ましい。溶媒としては化合物を分
解させることなく金属粉に対して安定なものであ
れば使用可能であり、好ましくはエタノール、プ
ロパノール、酢酸等のプロトン系溶媒又はこれら
と他の溶媒との混合物である。反応温度は室温乃
至加熱還流の間で適宜選択される。 In the step of obtaining a compound by treating a compound with a metal powder, the metal powder may be any powder having a dehalogenation ability, such as aene powder, copper powder, or tin powder, and these may be used alone or as a mixture. In addition,
Since the reaction occurs only on the surface of these metals, it is preferable that they be in the form of fine powder. As the solvent, any solvent can be used as long as it does not decompose the compound and is stable against the metal powder, preferably protic solvents such as ethanol, propanol, acetic acid, or mixtures of these and other solvents. The reaction temperature is appropriately selected between room temperature and heating to reflux.
反応混合物から化合物の単離は常法により、
例えば抽出、再結晶等の手段により容易に行うこ
とができる。 The compound is isolated from the reaction mixture by a conventional method.
For example, this can be easily carried out by means such as extraction and recrystallization.
実施例 １
1β，2β―エポキシコレスタ―５，７―ジエン
―3β―オールと４―フエニル―１，２，４―ト
リアゾリン―３，５―ジオンとの１，４―付加体
1.0ｇを氷酢酸５mlに懸濁し、激しく撹拌しなが
ら室温下47％臭化水素水0.5mlを氷酢酸１mlに溶
解した液を加える。５分後白色結晶が析出する。
クロロホルム１mlを加え更に５分間撹拌を続け、
10mlのクロロホルムを加える。反応混合物を２回
水洗した後クロロホルム層を硫酸マグネシウムで
乾燥し、溶媒を留去する。残渣にエタノールを加
え、析出した針状晶を過する。0.95ｇの1α―ブ
ロモコレスタ―５，７―ジエン―2β，3β―ジオ
ールと４―フエニル―１，２，４―トリアゾリン
―３，５―ジオンとの１，４―付加体を得た。Example 1 1β,2β-epoxy cholesta-5,7-dien-3β-ol and 1,4-adduct of 4-phenyl-1,2,4-triazoline-3,5-dione
Suspend 1.0 g in 5 ml of glacial acetic acid, and add a solution prepared by dissolving 0.5 ml of 47% hydrogen bromide in 1 ml of glacial acetic acid at room temperature while stirring vigorously. After 5 minutes, white crystals precipitate.
Add 1 ml of chloroform and continue stirring for another 5 minutes.
Add 10ml chloroform. After washing the reaction mixture twice with water, the chloroform layer was dried over magnesium sulfate, and the solvent was distilled off. Add ethanol to the residue and filter out the precipitated needle crystals. 0.95 g of a 1,4-adduct of 1α-bromocholester-5,7-diene-2β,3β-diol and 4-phenyl-1,2,4-triazoline-3,5-dione was obtained.
融点；202〜203℃（分解、エタノールから再結
晶）
NMRスペクトル（CDCl3）δ；7.32（5H，ｓ，
フエニル），6.30（2H，dd，６―７―Ｈ），
4.40（1H，ｂ，ｓ，１―Ｈ），3.5〜3.8
（2H，ｍ，２―，３―Ｈ），0.90（3H，ｓ，
CH3），0.81（3H，ｓ，CH3）
IRスペクトル（KBr）cm-1；3475（OH），
1743，1685（Ｃ＝０）
実施例 ２
1α―ブロモコレスタ―５，７―ジエン―2β，
3β―ジオールと４―フエニル―１，２，４―ト
リアゾリン―３，５―ジオンとの１，４―付加体
0.8ｇをエタノール５mlに懸濁したアエン末0.4ｇ
を加え撹拌しながら30分加熱還流する。氷酢酸
0.1mlを加え数分加熱した後デカントにより上澄
液をとる。残渣をクロロホルムで洗滌する。上澄
液とクロロホルム洗液とを合してクロロホルム抽
出する。クロロホルム層を水洗し、乾燥し、溶媒
を留去する。残渣をメタノールから再結晶しコレ
スタ―１，５，７―トリエン―3β―オールと４
―フエニル―１，２，４―トリアゾリン―３，５
―ジオンとの１，４―付加体0.64ｇを得た。 Melting point: 202-203℃ (decomposition, recrystallization from ethanol) NMR spectrum (CDCl 3 ) δ: 7.32 (5H, s,
phenyl), 6.30 (2H, dd, 6-7-H),
4.40 (1H, b, s, 1-H), 3.5-3.8
(2H, m, 2-, 3-H), 0.90 (3H, s,
CH 3 ), 0.81 (3H, s, CH 3 ) IR spectrum (KBr) cm -1 ; 3475 (OH),
1743, 1685 (C=0) Example 2 1α-bromocholester-5,7-diene-2β,
1,4-adduct of 3β-diol and 4-phenyl-1,2,4-triazoline-3,5-dione
0.4g of aene powder suspended in 5ml of ethanol
Add and heat to reflux for 30 minutes while stirring. glacial acetic acid
Add 0.1ml and heat for several minutes, then remove the supernatant by decantation. Wash the residue with chloroform. The supernatant liquid and the chloroform washing liquid are combined and extracted with chloroform. The chloroform layer is washed with water, dried, and the solvent is distilled off. The residue was recrystallized from methanol to give cholesta-1,5,7-trien-3β-ol and 4
-Phenyl-1,2,4-triazoline-3,5
-0.64 g of 1,4-adduct with dione was obtained.
融点：178〜182℃
NMRスペクトル（CDCl3）δ；7.33（5H，ｓ，
フエニル），6.31（2H，dd，６―，７―
Ｈ）、5.70（2H，ｓ，１―，２―Ｈ），3.34
（1H，dd，３―Ｈ）
IRスペクトル（KBr）cm-1；3450（OH），
1755，1700（Ｃ＝０）
実施例 ３
1β，2β―エポキシコレスタ―５，７―ジエン
―3β，25―ジオールと４―フエニル―１，２，
４―トリアゾリン―３，５―ジオンとの１，４―
付加体0.107ｇを氷酢酸１mlに溶解し、激しく撹
拌しながら47％臭化水素化0.03mlを氷酢酸0.5ml
に溶解したものを加え、室温で10分撹拌する。ク
ロロホルム20mlを加え、水洗する。硫酸マグネシ
ウムで乾燥し、溶媒を留去する。残渣をシリカゲ
ルカラムクロマトグラフイーに付し20％アセトン
含有クロロホルムで溶出し、目的物を含むフラク
シヨンを集め濃縮する。残渣をアセトン―エーテ
ルから再結晶すると1α―ブロモコレスタ―５，
７―ジエン―2β，3β，25―トリオールと４―フ
エニル―１，２，４―トリアゾリン―３，５―ジ
オンとの１，４―付加体41.4mgを得た。 Melting point: 178-182℃ NMR spectrum (CDCl 3 ) δ; 7.33 (5H, s,
phenyl), 6.31 (2H, dd, 6-, 7-
H), 5.70 (2H, s, 1-, 2-H), 3.34
(1H, dd, 3-H) IR spectrum (KBr) cm -1 ; 3450 (OH),
1755, 1700 (C=0) Example 3 1β,2β-epoxy cholester-5,7-diene-3β,25-diol and 4-phenyl-1,2,
1,4- with 4-triazoline-3,5-dione
Dissolve 0.107 g of the adduct in 1 ml of glacial acetic acid, and add 0.03 ml of 47% hydrobromide to 0.5 ml of glacial acetic acid while stirring vigorously.
Add the solution dissolved in and stir at room temperature for 10 minutes. Add 20ml of chloroform and wash with water. Dry over magnesium sulfate and evaporate the solvent. The residue is subjected to silica gel column chromatography, eluted with chloroform containing 20% acetone, and fractions containing the target product are collected and concentrated. When the residue was recrystallized from acetone-ether, 1α-bromocholester-5,
41.4 mg of a 1,4-adduct of 7-diene-2β,3β,25-triol and 4-phenyl-1,2,4-triazoline-3,5-dione was obtained.
融点；199〜201℃（分解）
NMRスペクトル（CDCl3）δ；7.34（5H，ｓ，
フエニル），6.28（2H，dd，６―，７―
Ｈ），4.34（1H，ｂ，ｓ，１―Ｈ），3.4〜
3.8（2H，ｍ，２―，３―Ｈ）
IRスペクトル（KBr）cm-1；3500（OH），
1740，1680（Ｃ＝０）
実施例 ４
1α―ブロモコレスタ―５，７―ジエン―2β，
3β，25―トリオールと４―フエニル―１，２，
４―トリアゾリン―３，５―ジオンとの１，４―
付加体41mgをエタノール２mlに懸濁させアエン末
20mgを加え撹拌しながら30分加熱還流する。氷酢
酸を0.1ml加え数分加熱し、上澄液にクロロホル
ム20mlを加える。クロロホルム層を水洗後、硫酸
マグネシウムで乾燥し、溶媒を留去する。メタノ
ールから再結晶すると30.9mgのコレスタ―１，
５，７―トリエン―3β，25―ジオールと４―フ
エニル―１，２，４―トリアゾリン―３，５―ジ
オンとの１，４―付加体を得た。 Melting point: 199-201℃ (decomposition) NMR spectrum ( CDCl3 ) δ: 7.34 (5H, s,
phenyl), 6.28 (2H, dd, 6-, 7-
H), 4.34 (1H, b, s, 1-H), 3.4~
3.8 (2H, m, 2-, 3-H) IR spectrum (KBr) cm -1 ; 3500 (OH),
1740, 1680 (C=0) Example 4 1α-bromocholester-5,7-diene-2β,
3β,25-triol and 4-phenyl-1,2,
1,4- with 4-triazoline-3,5-dione
Suspend 41 mg of adduct in 2 ml of ethanol and add aene powder.
Add 20 mg and heat to reflux for 30 minutes while stirring. Add 0.1 ml of glacial acetic acid and heat for several minutes, then add 20 ml of chloroform to the supernatant. After washing the chloroform layer with water, it is dried over magnesium sulfate, and the solvent is distilled off. When recrystallized from methanol, 30.9 mg of cholester-1,
A 1,4-adduct of 5,7-triene-3β,25-diol and 4-phenyl-1,2,4-triazoline-3,5-dione was obtained.
融点；159〜160℃
NMRスペクトル（CDCl3）δ；7.41（5H，ｓ，
フエニル），6.50，6.27（each 1H，ｄ，５
―，６―Ｈ），5.76（2H，ｓ，１―，２―
Ｈ），5.02（1H，ｍ，３―Ｈ），1.19（6H，
ｓ），1.07，0.80（each 3H，ｓ）
IRスペクトル（KBr）cm-1；3440（0H），1750，
1688（Ｃ＝０）
実施例 ５
1β，2β―エポキシコレクタ―3β，24ξ―ジオー
ルと４―フエニル―１，２，４―トリアゾリン―
３，５―ジオンとの１，４―付加体1.0ｇを氷酢
酸５mlに溶解し47％臭化水素水0.5mlを氷酢酸１
mlに溶解したものを加え室温で10分撹拌する。ク
ロロホルム20mlを加え水洗する。硫酸マグネシウ
ムで乾燥し、溶媒を留去する。残渣を５mlのエタ
ノールに溶解しアエン末0.4ｇを加え30分加熱還
流する。氷酢酸0.1mlを加え数分加熱した後上澄
液をとりクロロホルム20mlに加える。水洗した後
硫酸マグネシウムで乾燥する。クロロホルムを留
去した後残渣をシリカゲルカラムクロマトグラフ
イーに付し、20％アセトン含有クロロホルムで溶
出する。目的物のフラクシヨンを集め溶媒を留去
すると0.65ｇのコレスター１，５，７―トリエン
―3β，24ξ―ジオールと４―フエニル―１，２，
４―トリアゾリン―３，５―ジオンを得た。 Melting point: 159-160℃ NMR spectrum (CDCl 3 ) δ: 7.41 (5H, s,
phenyl), 6.50, 6.27 (each 1H, d, 5
-, 6-H), 5.76 (2H, s, 1-, 2-
H), 5.02 (1H, m, 3-H), 1.19 (6H,
s), 1.07, 0.80 (each 3H, s) IR spectrum (KBr) cm -1 ; 3440 (0H), 1750,
1688 (C=0) Example 5 1β,2β-epoxy collector-3β,24ξ-diol and 4-phenyl-1,2,4-triazoline-
Dissolve 1.0 g of 1,4-adduct with 3,5-dione in 5 ml of glacial acetic acid, add 0.5 ml of 47% hydrogen bromide solution to 1 ml of glacial acetic acid.
ml of the solution and stir at room temperature for 10 minutes. Add 20ml of chloroform and wash with water. Dry over magnesium sulfate and evaporate the solvent. Dissolve the residue in 5 ml of ethanol, add 0.4 g of aene powder, and heat under reflux for 30 minutes. Add 0.1 ml of glacial acetic acid and heat for several minutes, then remove the supernatant and add to 20 ml of chloroform. After washing with water, dry with magnesium sulfate. After chloroform was distilled off, the residue was subjected to silica gel column chromatography and eluted with chloroform containing 20% acetone. When fractions of the target product were collected and the solvent was distilled off, 0.65 g of cholester 1,5,7-triene-3β,24ξ-diol and 4-phenyl-1,2,
4-triazoline-3,5-dione was obtained.
融点：150〜156℃
NMRスペクトル（CDCl3）δ；7.38（5H，ｓ，
フエニル），6.45，6.25（ each 1H，ｄ，
６―，７―Ｈ），5.71（2H，ｓ，１―，２
―Ｈ），5.00（1H，ｍ，３―Ｈ），1.07（3H，
ｓ），0.88（6H，ｄ），0.82（3H，ｓ）
IRスペクトル（KBr）cm-1；3430（OH），
1752，1700（Ｃ＝０） Melting point: 150-156℃ NMR spectrum (CDCl 3 ) δ; 7.38 (5H, s,
phenyl), 6.45, 6.25 ( each 1H, d,
6-, 7-H), 5.71 (2H, s, 1-, 2
-H), 5.00 (1H, m, 3-H), 1.07 (3H,
s), 0.88 (6H, d), 0.82 (3H, s) IR spectrum (KBr) cm -1 ; 3430 (OH),
1752, 1700 (C=0)
Claims (1)
又は異なつて各々水素原子、水酸基および保護さ
れた水酸基を意味し、R3は水素原子又は水酸基
の保護基を意味する。） で示される1β，2β―エポキシコレスタ―3β―オ
ールステロイド誘導体を不活性溶媒中ハロゲン化
水素酸と反応させ一般式 （式中、Ｒ，R1，R2，R3は前記と同じものを
意味し、Ｘはハロゲン原子を意味する。） で示されるハロヒドリンステロイド誘導体とし、
次いで不活性溶媒中金属粉を反応させることを特
徴とする一般式 （式中、Ｒ，R1，R2，R3は前記と同じものを
意味する。） で示される１―エンステロイド誘導体の製法。[Claims] 1. General formula (In the formula, R means an organic residue, R 1 and R 2 are the same or different and each means a hydrogen atom, a hydroxyl group, or a protected hydroxyl group, and R 3 means a hydrogen atom or a protecting group for the hydroxyl group. ) The 1β,2β-epoxy cholesta-3β-allsteroid derivative represented by (In the formula, R, R 1 , R 2 , R 3 mean the same as above, and X means a halogen atom.) A halohydrin steroid derivative represented by
General formula characterized by then reacting metal powder in an inert solvent (In the formula, R, R 1 , R 2 and R 3 have the same meanings as above.) A method for producing a 1-ene steroid derivative.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP55129121A JPS5754200A (en) | 1980-09-19 | 1980-09-19 | Preparation of steroid derivative |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP55129121A JPS5754200A (en) | 1980-09-19 | 1980-09-19 | Preparation of steroid derivative |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS5754200A JPS5754200A (en) | 1982-03-31 |
| JPS6351157B2 true JPS6351157B2 (en) | 1988-10-13 |
Family
ID=15001588
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP55129121A Granted JPS5754200A (en) | 1980-09-19 | 1980-09-19 | Preparation of steroid derivative |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPS5754200A (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4728331B2 (en) * | 2005-06-16 | 2011-07-20 | 裕 片岡 | Sound absorption structure |
-
1980
- 1980-09-19 JP JP55129121A patent/JPS5754200A/en active Granted
Also Published As
| Publication number | Publication date |
|---|---|
| JPS5754200A (en) | 1982-03-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR102526631B1 (en) | 6-alkyl-7-hydroxy-4-en-3-one steroids as intermediates for the production of steroidal fxr modulators | |
| KR102526632B1 (en) | 5.beta.-6-alkyl-7-hydroxy-3-one steroids as intermediates for the production of steroidal fxr modulators | |
| KR102527821B1 (en) | 6.alpha.-alkyl-6,7-dione steroids as intermediates for the production of steroidal fxr modulators | |
| KR102546748B1 (en) | 6.alpha.-alkyl-3,7-dione steroids as intermediates for the production of steroidal fxr modulators | |
| HUE029252T2 (en) | Process for the production of estetrol intermediates | |
| HUE031809T2 (en) | Process for the production of estetrol intermediates | |
| JPH0742305B2 (en) | 25,26,27-trinorcholesterol compound | |
| RU2127739C1 (en) | PROCESS FOR PREPARING 6α,9α-DIFLUORINATED STEROIDS AND INTERMEDIATE COMPOUNDS | |
| EP0056000B1 (en) | 17-(alkoxycarbonyl)(formamide)methylene steroid derivatives and their preparation | |
| FR2505847A1 (en) | 21-HALOGENO-ALLENE SULFOXIDE AND METHOD FOR SYNTHESIS | |
| DE69005709T2 (en) | Adductaldehyde and its application in the production of vitamin D derivatives. | |
| JPS6351157B2 (en) | ||
| JPH07503466A (en) | Novel steroid intermediate and its production method | |
| JP3037508B2 (en) | Novel substituted 16-methyl steroid derivatives of pregna-1,4-diene-3,20-dione, their preparation, their use in the preparation of 16-methylene steroids and novel intermediates | |
| JPS5823660A (en) | Manufacture of 1 alpha-hydroxyvitamin d or 1 alpha-hydroxy-previtamin d compound and adduct of previtamin d or tachysterol and dienophile | |
| EP3063166B1 (en) | Method for preparing 6-alkylated steroidal derivatives and corresponding alkylated 5,6,7,8-tetrahydronaphthalene-2(4 alpha.h)-ones | |
| JPS58219196A (en) | Production of 4'-demethyl-epipodophyllotoxin-beta-d- ethylideneglucoside | |
| US3817988A (en) | PROCESS FOR 11,12-ENOLISATION OF 9a-HALO-11-KETO-STEROIDS | |
| EP0045524A1 (en) | 22-Arylsulfonyl-24,25-dihydroxycholestanes and process for preparing the same | |
| HU187843B (en) | Process for producing 17-alpha-hydroxy-17-beta-bracket-hydroxy-acetyl-bracket closed-steroides | |
| US6790843B1 (en) | C-19-halogen-substituted steroids of the androst-9(11)-ene-series, methods for the production and use thereof | |
| JPS6111959B2 (en) | ||
| CA1225635A (en) | Process for preparing prednisone derivatives | |
| JPH0318625B2 (en) | ||
| JPS58126862A (en) | Manufacture of 1-hydroxylated vitamine d compound |